Erythropoietin (EPO) is a medication used to stimulate the production of new red blood cells, which is impaired in individuals with kidney failure. Unfortunately, however, the treatment may increase the risk of hip fractures.
In an analysis published in the Journal of Bone and Mineral Research that examined 1997-2013 records from two large U.S. databases, investigators found that EPO doses administered to patients with kidney failure on hemodialysis fluctuated widely over time, and hip fracture rates closely tracked the average dose of EPO doses used in patients.
'Patients with renal failure can benefit from EPO treatment; however, as with all medications, a full understanding of potential drug-associated risks favors the likelihood that a positive risk-benefit balance can be achieved with EPO treatment,' senior author Constance Tom Noguchi, PhD, of the National Institute of Diabetes and Digestive and Kidney Diseases.
Link to Study: https://onlinelibrary.wiley.com/doi/10.1002/jbmr.4297
The Journal of Bone and Mineral Research (JBMR) publishes highly impactful original manuscripts, reviews, and special articles on basic, translational and clinical investigations relevant to the musculoskeletal system and mineral metabolism. Specifically, the journal is interested in original research on the biology and physiology of skeletal tissues, interdisciplinary research spanning the musculoskeletal and other systems, including but not limited to immunology, hematology, energy metabolism, cancer biology, and neurology, and systems biology topics using large scale '-omics' approaches. The journal welcomes clinical research on the pathophysiology, treatment and prevention of osteoporosis and fractures, as well as sarcopenia, disorders of bone and mineral metabolism, and rare or genetically determined bone diseases.
Wiley drives the world forward with research and education. Through publishing, platforms and services, we help students, researchers, universities, and corporations to achieve their goals in an ever-changing world. For more than 200 years, we have delivered consistent performance to all of our stakeholders. The Company's website can be accessed at www.wiley.com.
John Wiley & Sons Inc. published this content on 05 May 2021 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 05 May 2021 05:08:02 UTC.